SAN FRANCISCO, CA—Administering low-dose alteplase directly into the artery prior to PCI in patients with STEMI and a large thrombus burden fails to lower the risk of a range of outcomes, including ...
A major international analysis of 2,313 patients, median age 71, found that giving an IV clot-busting drug before mechanical clot removal modestly increases brain-bleeding risk compared with ...
Intravenous alteplase is beneficial for patients who present with an acute ischemic stroke and salvageable brain tissue on imaging—with or without a large-vessel occlusion (LVO)—up to 24 hours after ...
Genetically altering crops may be key to helping them adapt to extreme temperatures. But shrinking funds and social acceptance stand in the way. By Rebecca Dzombak The world’s bread baskets are ...
A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ischemic stroke have been granted approval by the US Food and Drug ...
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...
Over nearly the last three decades, Genentech has had the lone medicine on the market for the acute treatment of stroke. Monday, the Roche subsidiary added a second stroke treatment to its repertoire, ...
Researchers found that the percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days was 40.3 and 26.3% in the alteplase and standard medical treatment groups, ...
LOS ANGELES -- The HOPE trial made another case for extending the therapeutic window for IV thrombolysis in acute ischemic stroke, potentially widening the pool of people eligible for therapy. Among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback